Overview

  • Product name
    Anti-HIP2 antibody [EP1145Y]
    See all HIP2 primary antibodies
  • Description
    Rabbit monoclonal [EP1145Y] to HIP2
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IP, IHC-P, ICC/IFmore details
    Unsuitable for: Flow Cyt
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human HIP2 aa 150-250 (internal sequence). The exact sequence is proprietary.

  • Positive control
    • Daudi cell lysate or human liver tissue.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab52930 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100000. Detects a band of approximately 24 kDa (predicted molecular weight: 22 kDa).
IP 1/50.
IHC-P 1/250 - 1/500. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
ICC/IF 1/250.
  • Application notes
    Is unsuitable for Flow Cyt.
  • Target

    • Function
      Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro, in the presence or in the absence of BRCA1-BARD1 E3 ubiquitin-protein ligase complex, catalyzes the synthesis of 'Lys-48'-linked polyubiquitin chains. Does not transfer ubiquitin directly to but elongates monoubiquitinated substrate protein. Mediates the selective degradation of short-lived and abnormal proteins, such as the endoplasmic reticulum-associated degradation (ERAD) of misfolded lumenal proteins. Ubiquitinates huntingtin. May mediate foam cell formation by the suppression of apoptosis of lipid-bearing macrophages through ubiquitination and subsequence degradation of p53/TP53. Proposed to be involved in ubiquitination and proteolytic processing of NF-kappa-B; in vitro supports ubiquitination of NFKB1. In case of infection by cytomegaloviruses may be involved in the US11-dependent degradation of MHC class I heavy chains following their export from the ER to the cytosol. In case of viral infections may be involved in the HPV E7 protein-dependent degradation of RB1.
    • Tissue specificity
      Expressed in all tissues tested, including spleen, thymus, prostate, testis, ovary, small intestine, colon, peripheral blood leukocytes, T-lymphocytes, monocytes, granulocytes and bone marrow mononuclear cells. Highly expressed in brain, with highest levels found in cortex and striatum and at lower levels in cerebellum and brainstem.
    • Pathway
      Protein modification; protein ubiquitination.
    • Sequence similarities
      Belongs to the ubiquitin-conjugating enzyme family.
      Contains 1 UBA domain.
    • Post-translational
      modifications
      Sumoylation at Lys-14 impairs catalytic activity.
    • Cellular localization
      Cytoplasm.
    • Information by UniProt
    • Database links
    • Alternative names
      • E2 25K antibody
      • E2(25K) antibody
      • HIP-2 antibody
      • Huntingtin interacting protein 2 antibody
      • Huntingtin-interacting protein 2 antibody
      • HYPG antibody
      • LIG antibody
      • UBC1 antibody
      • UBE2K antibody
      • UBE2K_HUMAN antibody
      • Ubiquitin carrier protein antibody
      • Ubiquitin conjugating enzyme E2 25 kDa antibody
      • ubiquitin conjugating enzyme E2K antibody
      • ubiquitin conjugating enzyme E2K (UBC1 homolog, yeast) antibody
      • Ubiquitin protein ligase antibody
      • Ubiquitin-conjugating enzyme E2 K antibody
      • Ubiquitin-conjugating enzyme E2(25K) antibody
      • Ubiquitin-conjugating enzyme E2-25 kDa antibody
      • Ubiquitin-conjugating enzyme E2-25K antibody
      • Ubiquitin-protein ligase antibody
      see all

    Images

    • Anti-HIP2 antibody [EP1145Y] (ab52930) at 1/100000 dilution + Daudi cell lysate at 10 µg

      Secondary
      Goat anti-Rabbit HRP labeled at 1/2000 dilution

      Predicted band size: 22 kDa
      Observed band size: 24 kDa
      why is the actual band size different from the predicted?

    • Ab52930 (1:250) staining human HIP2 in human liver tissue by immunohistochemistry using paraffin embedded tissue.

    References

    This product has been referenced in:
    • McManus FP  et al. Quantitative SUMO proteomics reveals the modulation of several PML nuclear body associated proteins and an anti-senescence function of UBC9. Sci Rep 8:7754 (2018). Read more (PubMed: 29773808) »
    • Benedikt A  et al. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia 25:135-44 (2011). WB ; Human . Read more (PubMed: 21030982) »
    See all 2 Publications for this product

    Customer reviews and Q&As

    1-2 of 2 Abreviews or Q&A

    Application
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Sample
    Mouse Tissue sections (Brain)
    Antigen retrieval step
    None
    Permeabilization
    Yes - 10% Tween-20
    Specification
    Brain
    Blocking step
    Heat-Inactivated Normal Donkey Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Fixative
    Paraformaldehyde

    Abcam user community

    Verified customer

    Submitted Jan 22 2016

    Answer

    The antibody ab52930 is raised against a peptide located within the range of amino acids 140 - 170 of human HIP2/E2-25K, http://www.uniprot.org/uniprot/P61086. There are no known issues of detection of SUMOylated samples. I am not sure what is happening that would cause the signal to be fainter, unless there is some modification or degradation at or near the epitope that the antibody recognizes that only exists in the samples that are SUMOylated at Lys 14.

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up